Eupraxia Pharmaceuticals Inc. Company Profile
NASDAQ: EPRXHealth CarePharmaceuticals and BiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Eupraxia Pharmaceuticals at a glance
Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX) is a Pharmaceuticals and Biotechnology company in the Health Care sector headquartered in Victoria, BC, Canada. Eupraxia Pharmaceuticals is led by Dr. James A. Helliwell FRCPC, M.D. and employs about 49 people. At a market capitalization of $510.1 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001581178, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Eupraxia Pharmaceuticals do?
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Business description based on the company's public filings.
Company information
- Legal name
- Eupraxia Pharmaceuticals Inc.
- Ticker
- NASDAQ: EPRX
- Sector
- Health Care
- Industry
- Pharmaceuticals and Biotechnology
- CEO
- Dr. James A. Helliwell FRCPC, M.D.
- Employees
- 49
- Headquarters
- 2067 Cadboro Bay Road, Victoria, BC, Canada
- Phone
- 250 590 3968
- Website
- eupraxiapharma.com
- Market cap
- $510.12M
- SEC CIK
- 0001581178